JAMA,
Journal Year:
2017,
Volume and Issue:
317(23), P. 2392 - 2392
Published: June 20, 2017
Importance
Combining
biologic
monoclonal
antibodies
with
chemotherapeutic
cytotoxic
drugs
provides
clinical
benefit
to
patients
advanced
or
metastatic
colorectal
cancer,
but
the
optimal
choice
of
initial
therapy
in
previously
untreated
is
unknown.
Objective
To
determine
if
addition
cetuximab
vs
bevacizumab
combination
leucovorin,
fluorouracil,
and
oxaliplatin
(mFOLFOX6)
regimen
irinotecan
(FOLFIRI)
superior
as
first-line
metastaticKRASwild-type
(wt)
cancer.
Design,
Setting,
Participants
Patients
(≥18
years)
enrolled
at
community
academic
centers
throughout
National
Clinical
Trials
Network
United
States
Canada
(November
2005-March
2012)
cancer
whose
tumors
wereKRASwt
chose
take
either
mFOLFOX6
FOLFIRI
chemotherapy
were
randomized
receive
(n
=
578)
559).
The
last
date
follow-up
was
December
15,
2015.
Interventions
Cetuximab
combined
chosen
by
treating
physician
patient.
Main
Outcomes
Measures
primary
end
point
overall
survival.
Secondary
objectives
included
progression-free
survival
response
rate,
site-reported
confirmed
unconfirmed
complete
partial
response.
Results
Among
1137
(median
age,
59
years;
440
[39%]
women),
1074
(94%)
met
eligibility
criteria.
As
2015,
median
for
263
surviving
47.4
months
(range,
0-110.7
months),
82%
(938
1137)
experienced
disease
progression.
30.0
cetuximab-chemotherapy
group
29.0
bevacizumab-chemotherapy
a
stratified
hazard
ratio
(HR)
0.88
(95%
CI,
0.77-1.01;P
.08).
10.5
10.6
HR
0.95
0.84-1.08;P
.45).
Response
rates
not
significantly
different,
59.6%
55.2%
bevacizumab,
respectively
(difference,
4.4%,
95%
1.0%-9.0%,P
.13).
Conclusions
Relevance
withKRASwt
there
no
significant
difference
between
treatment.
Signal Transduction and Targeted Therapy,
Journal Year:
2020,
Volume and Issue:
5(1)
Published: March 20, 2020
Abstract
Colorectal
cancer
(CRC)
is
among
the
most
lethal
and
prevalent
malignancies
in
world
was
responsible
for
nearly
881,000
cancer-related
deaths
2018.
Surgery
chemotherapy
have
long
been
first
choices
patients.
However,
prognosis
of
CRC
has
never
satisfying,
especially
patients
with
metastatic
lesions.
Targeted
therapy
a
new
optional
approach
that
successfully
prolonged
overall
survival
Following
successes
anti-EGFR
(epidermal
growth
factor
receptor)
agent
cetuximab
anti-angiogenesis
bevacizumab,
agents
blocking
different
critical
pathways
as
well
immune
checkpoints
are
emerging
at
an
unprecedented
rate.
Guidelines
worldwide
currently
updating
recommended
targeted
drugs
on
basis
increasing
number
high-quality
clinical
trials.
This
review
provides
overview
existing
CRC-targeted
their
underlying
mechanisms,
discussion
limitations
future
trends.
Genome Medicine,
Journal Year:
2019,
Volume and Issue:
11(1)
Published: May 24, 2019
We
introduce
quanTIseq,
a
method
to
quantify
the
fractions
of
ten
immune
cell
types
from
bulk
RNA-sequencing
data.
quanTIseq
was
extensively
validated
in
blood
and
tumor
samples
using
simulated,
flow
cytometry,
immunohistochemistry
data.quanTIseq
analysis
8000
revealed
that
cytotoxic
T
infiltration
is
more
strongly
associated
with
activation
CXCR3/CXCL9
axis
than
mutational
load
deconvolution-based
scores
have
prognostic
value
several
solid
cancers.
Finally,
we
used
show
how
kinase
inhibitors
modulate
contexture
reveal
immune-cell
underlie
differential
patients'
responses
checkpoint
blockers.Availability:
available
at
http://icbi.at/quantiseq
.
European Urology,
Journal Year:
2019,
Volume and Issue:
77(4), P. 420 - 433
Published: Sept. 26, 2019
Muscle-invasive
bladder
cancer
(MIBC)
is
a
molecularly
diverse
disease
with
heterogeneous
clinical
outcomes.
Several
molecular
classifications
have
been
proposed,
but
the
diversity
of
their
subtype
sets
impedes
application.
To
achieve
an
international
consensus
on
MIBC
subtypes
that
reconciles
published
classification
schemes.
We
used
1750
transcriptomic
profiles
from
16
datasets
and
two
additional
cohorts.
performed
network-based
analysis
six
independent
systems
to
identify
set
classes.
Association
survival
was
assessed
using
multivariable
Cox
models.
report
results
effort
reach
subtypes.
identified
classes:
luminal
papillary
(24%),
nonspecified
(8%),
unstable
(15%),
stroma-rich
basal/squamous
(35%),
neuroendocrine-like
(3%).
These
classes
differ
regarding
underlying
oncogenic
mechanisms,
infiltration
by
immune
stromal
cells,
histological
characteristics,
including
provide
single-sample
classifier
assigns
class
label
tumor
sample's
transcriptome.
Limitations
work
are
retrospective
data
collection
lack
complete
information
patient
treatment.
This
system
offers
robust
framework
will
enable
testing
validation
predictive
biomarkers
in
future
prospective
trials.
Bladder
cancers
at
level,
scientists
proposed
several
into
While
these
may
be
useful
stratify
patients
for
prognosis
or
response
treatment,
would
facilitate
use
Conducted
multidisciplinary
expert
teams
field,
this
study
proposes
such
provides
tool
applying
setting.
